Literature DB >> 22031951

Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

George Sellhorn1, Zane Kraft, Zachary Caldwell, Katharine Ellingson, Christine Mineart, Michael S Seaman, David C Montefiori, Eliza Lagerquist, Leonidas Stamatatos.   

Abstract

The envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) is composed of two noncovalently associated subunits: an extracellular subunit (gp120) and a transmembrane subunit (gp41). The functional unit of Env on the surface of infectious virions is a trimer of gp120/gp41 heterodimers. Env is the target of anti-HIV neutralizing antibodies. A considerable effort has been invested in the engineering of recombinant soluble forms of the virion-associated Env trimer as vaccine candidates to elicit anti-HIV neutralizing antibody responses. These soluble constructs contain three gp120 subunits and the extracellular segments of the corresponding gp41 subunits. The individual gp120/gp41 protomers on these soluble trimers are identical in amino acid sequence (homotrimers). Here, we engineered novel soluble trimeric gp140 proteins that are formed by the association of gp140 protomers that differ in amino acid sequence and glycosylation patterns (heterotrimers). Specifically, we engineered soluble heterotrimeric proteins composed of clade A and clade B Env protomers. The clade A gp140 protomers were derived from viruses isolated during acute infection (Q168a2, Q259d2.17, and Q461e2), whereas the clade B gp140 protomers were derived from a virus isolated during chronic infection (SF162). The amino acid sequence divergence between the clade A and the clade B Envs is approximately 24%. Neutralization epitopes in the CD4 binding sites and coreceptor binding sites, as well as the membrane-proximal external region (MPER), were differentially expressed on the heterotrimeric and homotrimeric proteins. The heterotrimeric gp140s elicited broader anti-tier 1 isolate neutralizing antibody responses than did the homotrimeric gp140s.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22031951      PMCID: PMC3255899          DOI: 10.1128/JVI.06363-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.

Authors:  L Stamatatos; M Lim; C Cheng-Mayer
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-01       Impact factor: 2.205

3.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

5.  Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.

Authors:  S Lu; R Wyatt; J F Richmond; F Mustafa; S Wang; J Weng; D C Montefiori; J Sodroski; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  1998-01-20       Impact factor: 2.205

6.  Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.

Authors:  R R Garrity; G Rimmelzwaan; A Minassian; W P Tsai; G Lin; J J de Jong; J Goudsmit; P L Nara
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

7.  Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Authors:  M W Cho; Y B Kim; M K Lee; K C Gupta; W Ross; R Plishka; A Buckler-White; T Igarashi; T Theodore; R Byrum; C Kemp; D C Montefiori; M A Martin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.

Authors:  K Salzwedel; E A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

9.  Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

Authors:  T C VanCott; J R Mascola; R W Kaminski; V Kalyanaraman; P L Hallberg; P R Burnett; J T Ulrich; D J Rechtman; D L Birx
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

10.  Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor.

Authors:  C Cheng-Mayer; R Liu; N R Landau; L Stamatatos
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

View more
  21 in total

1.  Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Authors:  Daniel P Leaman; Jeong Hyun Lee; Andrew B Ward; Michael B Zwick
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

2.  Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.

Authors:  Axel Mann; Nikolas Friedrich; Anders Krarup; Jacqueline Weber; Emanuel Stiegeler; Birgit Dreier; Pavel Pugach; Melissa Robbiani; Tina Riedel; Kerstin Moehle; John A Robinson; Peter Rusert; Andreas Plückthun; Alexandra Trkola
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

3.  Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

Authors:  Andrew T McGuire; Jolene A Glenn; Adriana Lippy; Leonidas Stamatatos
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

4.  Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.

Authors:  Ganesh E Phad; Néstor Vázquez Bernat; Yu Feng; Jidnyasa Ingale; Paola Andrea Martinez Murillo; Sijy O'Dell; Yuxing Li; John R Mascola; Christopher Sundling; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Immunol       Date:  2015-05-11       Impact factor: 5.422

5.  Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.

Authors:  Rangasamy Sneha Priya; Menon Veena; Irene Kalisz; Stephen Whitney; Dhopeshwarkar Priyanka; Celia C LaBranche; Mullapudi Sri Teja; David C Montefiori; Ranajit Pal; Sundarasamy Mahalingam; Vaniambadi S Kalyanaraman
Journal:  J Biol Chem       Date:  2015-02-17       Impact factor: 5.157

6.  Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity.

Authors:  Wenjin Guo; Brad Cleveland; Thaddeus M Davenport; Kelly K Lee; Shiu-Lok Hu
Journal:  Protein Expr Purif       Date:  2013-05-09       Impact factor: 1.650

7.  ARTEMIS: A Novel Mass-Spec Platform for HLA-Restricted Self and Disease-Associated Peptide Discovery.

Authors:  Kathryn A K Finton; Mi-Youn Brusniak; Lisa A Jones; Chenwei Lin; Andrew J Fioré-Gartland; Chance Brock; Philip R Gafken; Roland K Strong
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

8.  Controlling the HIV/AIDS epidemic: current status and global challenges.

Authors:  Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

9.  Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

Authors:  Sam Hoot; Andrew T McGuire; Kristen W Cohen; Roland K Strong; Lars Hangartner; Florian Klein; Ron Diskin; Johannes F Scheid; D Noah Sather; Dennis R Burton; Leonidas Stamatatos
Journal:  PLoS Pathog       Date:  2013-01-03       Impact factor: 6.823

10.  A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.

Authors:  David Lutje Hulsik; Ying-ying Liu; Nika M Strokappe; Simone Battella; Mohamed El Khattabi; Laura E McCoy; Charles Sabin; Andreas Hinz; Miriam Hock; Pauline Macheboeuf; Alexandre M J J Bonvin; Johannes P M Langedijk; David Davis; Anna Forsman Quigley; Marlén M I Aasa-Chapman; Michael S Seaman; Alejandra Ramos; Pascal Poignard; Adrien Favier; Jean-Pierre Simorre; Robin A Weiss; C Theo Verrips; Winfried Weissenhorn; Lucy Rutten
Journal:  PLoS Pathog       Date:  2013-03-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.